1. Uremic Sarcopenia as a Clinical Entity {#sec1-nutrients-12-01814}
=========================================

"Sarcopenia" is derived from the Greek word for "muscle loss" as a combination of "sarx" for meat and muscle and "penia" for loss \[[@B1-nutrients-12-01814]\]. This concept was originally proposed by Rosenberg \[[@B2-nutrients-12-01814]\] and denotes a syndrome characterized by a progressive and systemic decrease in muscle mass and strength, leading to physical dysfunction, poor quality of life (QOL), and the risk of death. Age-related muscle loss is classified as primary sarcopenia, while that associated with a physical handicap or chronic illness is classified as secondary sarcopenia. The diagnostic criteria of the European Working Group on Sarcopenia in Older People (EWGSOP) are used globally \[[@B3-nutrients-12-01814]\], while, considering the differences in physique between races or ethnicities, for instance, the criteria developed by the Asian Working Group for Sarcopenia (AWGS) are recommended for Asians \[[@B4-nutrients-12-01814]\]. Many measures of skeletal muscle mass are quantitated with a cut-off value from the dual-energy X-ray absorptiometry (DEXA) method, while others adopt a cut-off value using the bioelectrical impedance analysis (BIA) method with a mathematical equation based on upper arm circumference and subcutaneous fat, in conjunction with a subjective global assessment.

Chronic kidney disease (CKD) is one of the chronic illnesses which complicates sarcopenia \[[@B5-nutrients-12-01814]\]. According to NHANES III (1994--1998), muscle mass is frequently reduced in CKD patients who have a reduction in glomerular filtration rate (GFR) or progression of albuminuria \[[@B6-nutrients-12-01814]\]. Another cohort study illustrated that walking speed and muscular strength deteriorated in those with 60--89 mL/min/1.73 m^2^ and below 60 mL/min/1.73 m^2^, compared to those with a creatinine clearance of 90 mL/min/1.73 m^2^ or more \[[@B7-nutrients-12-01814]\]. According to an observational study analyzing pre-dialysis CKD patients who were provided only minimal dietary counseling by health professionals, lower GFR was significantly associated with a spontaneous lower protein intake \[[@B8-nutrients-12-01814]\]. The authors warranted that dietary protein restriction should be carefully introduced for advanced CKD patients because their spontaneous protein intake is already low. According to the Korea National Health and Nutrition Examination Survey (KNHANES), the frequency of muscle loss decreases as the stage of CKD progresses, showing a 2.6%, 5.6%, 18.1% decrease in frequency in male G1 (estimated GFR \>90 mL/min/1.73 m^2^), G2 (60 to 90 mL/min/1.73 m^2^), and G3 to G5 (\<60 mL/min/1.73 m^2^), respectively \[[@B9-nutrients-12-01814]\]. Collectively, however, sarcopenia prevalence is greater in CKD patients than in the general population and increases with CKD advancement.

Unfortunately, the prognosis of CKD patients with sarcopenia is not promising in terms of mortality and length of hospital stay. In a report examining urinary creatinine excretion as an indicator of skeletal muscle mass in a body, the risk of death increased as urinary creatinine excretion decreased \[[@B10-nutrients-12-01814]\]. In CKD stages G3 to G5 diagnosed with sarcopenia based on the BIA method, muscular complication is associated with a poor prognosis \[[@B11-nutrients-12-01814]\]. Additionally, CKD patients with reduced physical functions, such as walking speed and grip strength, have a worse prognosis than those with CKD where those functions are retained \[[@B12-nutrients-12-01814]\]. According to epidemiological studies on end-stage renal disease, the incidence of sarcopenia increases as renal function deteriorates \[[@B13-nutrients-12-01814]\] and the incidence in elderly hemodialysis (HD) patients is significantly heightened \[[@B14-nutrients-12-01814]\]. The importance of uremic sarcopenia lies in its impact on mortality and morbidity, including susceptibility to fractures that affect the QOL for CKD patients \[[@B15-nutrients-12-01814]\], cardiovascular events \[[@B16-nutrients-12-01814]\], and overall survival \[[@B17-nutrients-12-01814]\].

Epidemiological studies have illustrated that quite a few factors may contribute to the increased incidence of sarcopenia in CKD patients, including limited protein intake, energy deficiency, aging, insufficient or deficient exercise, inflammation, metabolic acidosis, lack of natural vitamin D, and even diuretic treatment \[[@B18-nutrients-12-01814],[@B19-nutrients-12-01814],[@B20-nutrients-12-01814]\]. Additionally, abnormal lipid metabolism and obesity are frequently associated with sarcopenia in advanced CKD patients \[[@B21-nutrients-12-01814]\]. Truncal deposit of fat is also related to high blood levels of hepatic growth factor (HGF). HGF serves as a marker for obesity in the general population, and is predictive of mortality in catabolic conditions \[[@B22-nutrients-12-01814],[@B23-nutrients-12-01814]\]. Similarly, the concept of sarcopenia obesity attracts attention as a condition that has both skeletal muscle loss and increased body fat, and, however, it has been reported that sarcopenia obesity is not a risk for mortality in CKD patients \[[@B24-nutrients-12-01814]\]. In the United States, obesity is high in both the general population and CKD patients, and the study may include sarcopenia obesity.

Uremic myopathy, a term similar to uremic sarcopenia is a defined skeletal complication in CKD patients \[[@B25-nutrients-12-01814],[@B26-nutrients-12-01814]\]. Both are associated with a variety of muscular symptoms including weakness or atrophy in uremic patients, although uremic myopathy may focus on the disease per se regardless of any local or systemic impairment. Sarcopenia implies more systemic and dysfunctional disorders that are also defined by international guidelines. However, uremic sarcopenia and uremic myopathy can be hard to distinguish, particularly in laboratory research.

2. Nutritional Therapy for Uremic Sarcopenia: The Protein Intake Dilemma {#sec2-nutrients-12-01814}
========================================================================

Protein intake adjustment and energy levels play a key role in diet therapy for CKD. Several meta-analyses concluded that a low protein diet is effective in reducing composite endpoints including mortality in nondiabetic CKD patients \[[@B27-nutrients-12-01814],[@B28-nutrients-12-01814]\]. The Modification of Diet in Renal Disease (MDRD) study provided significant evidence more consistent with the hypothesis of a beneficial effect of protein restriction \[[@B29-nutrients-12-01814],[@B30-nutrients-12-01814]\]. One recent major review maintains that it is the patient's preference to adopt dietary interventions for the conservative management of uremia \[[@B31-nutrients-12-01814]\]. Notably, a small number of RCTs have been reported, in which strict protein restriction (\<0.6 g/kg/day), in combination with a keto acid supplement, was able to postpone ESRD and reduce the rate of renal function decline in advanced CKD \[[@B32-nutrients-12-01814],[@B33-nutrients-12-01814]\]. Unfortunately, not all CKD patients may be capable of undertaking this strict approach for an extended period of time.

For metabolically stable adults with CKD, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) plans to recommend prescribing an energy intake of 25 to 35 kcal/kg lean body mass (LBM) per day based on age, gender, level of physical activity, body composition, weight status goals, CKD stage, and concurrent illness or presence of inflammation to maintain normal nutritional requirements \[[@B34-nutrients-12-01814]\]. As for protein intake, in metabolically stable adults with CKD 3--5, they recommend protein restriction supervised by a registered dietitian nutritionist (RDN) or equivalent in collaboration with a physician, suggesting a low protein diet providing 0.55 to 0.60 g dietary protein/kg ideal body weight/day, or a very-low protein diet providing 0.28 to 0.43 g dietary protein/kg ideal body weight (IBW)/day with additional keto acid analogs to meet protein requirements (0.55 to 0.60 g/kg body weight/day). For metabolically stable adults with CKD on maintenance hemodialysis (MHD), they recommend prescribing a dietary protein intake of 1.0 to 1.2 g/kg ideal body weight per day. Having diabetes is not regarded as metabolically stable, so for the adults with CKD who have diabetes, NKF-KDOQI presents the option of prescribing a greater amount of dietary protein intake of 0.8 to 0.9 g/kg of ideal body weight per day.

Sarcopenia may present a more complex status in terms of metabolic stability, as skeletal protein catabolism is predominant in protein synthesis and degradation. For elderly people without CKD, adequate protein intake of 1.0 to 1.2 g/kg/day is considered effective for the prevention and improvement of sarcopenia \[[@B35-nutrients-12-01814]\], which is clearly incompatible with the protein restriction mentioned as a diet recommended for CKD patients. Thus, dietary therapy for uremic sarcopenia has not been well established. Strict adherence to any nutritional guidance on protein restriction is inappropriate and the disease activity, risk, and compliance of individual patients should be taken into consideration. An individual approach is essential to evaluate the risks of both CKD and sarcopenia and to select an appropriate protein intake for each patient.

3. Physical Exercise to Prevent or Regress Uremic Sarcopenia {#sec3-nutrients-12-01814}
============================================================

Exercise therapy is designated to enhance or maintain muscle strength, or at least to halt the progression of muscular function loss, which is expected to play a beneficial role in uremic sarcopenia. In addition to mortality or renal prognosis, as endpoints that pertain to physical activity, cardiopulmonary function, walking capacity, and skeletal muscle strength and mass are evaluated. In a cardiopulmonary exercise test, VO~2~ peak or VO~2~ max (representing the maximum rate of oxygen consumption measured during incremental exercise) is the most frequently monitored. For evaluation of walking capacity, the six minute walk test and walking speed measurement are frequently adopted. Muscular strength is measured mainly with a handheld dynamometer, although manual muscle testing and other types of dynamometry are conventionally available. Additionally, physical activity is assessed as a part of the QOL evaluation with the Kidney Disease Quality of Life instrument (KDQOL) \[[@B36-nutrients-12-01814]\].

For aging sarcopenia, multiple meta-analyses showed no obvious effect of diet alone on improving skeletal muscle mass, physical function, and muscle strength and, therefore, nutrition should be combined with physical exercise therapy when treating sarcopenia \[[@B37-nutrients-12-01814],[@B38-nutrients-12-01814],[@B39-nutrients-12-01814],[@B40-nutrients-12-01814],[@B41-nutrients-12-01814],[@B42-nutrients-12-01814],[@B43-nutrients-12-01814]\]. For uremic sarcopenia, a series of small size cohort studies analyzed the exercise effect on mortality, renal prognosis, physical activity, and QOL in patients with various stages of CKD ([Table 1](#nutrients-12-01814-t001){ref-type="table"}).

In most clinical trials, physical exercise therapy is implemented as resistance training, aerobic exercise, or both ([Figure 1](#nutrients-12-01814-f001){ref-type="fig"}). While resistance exercise consists of a moving the target musclesby squeezing handgrips and raising dumbbells repeatedly, the aerobic exercise involves stomping and slowly raising and lowering the legs. The training program should be systemic with plans to progressively address the CKD patients' weaknesses and to maximally condition the patients for participation in regular activities. Since CKD patients are usually elderly, supervised and personalized exercise is highly recommended.

3.1. Exercise for Patients with Pre-Dialysis CKD {#sec3dot1-nutrients-12-01814}
------------------------------------------------

A recent study with pre-dialysis CKD patients revealed that home-based aerobic and resistance exercises increased grip strength and knee extension muscle strength \[[@B44-nutrients-12-01814]\]. Self-administered exercise training programs were shown to improve handgrip and isometric quadriceps strength \[[@B45-nutrients-12-01814]\]. Another study of patients with CKD stage G3b to G4 indicates that muscle anatomical cross-sectional area, muscle volume, and knee extensor strength are increased by a supervised progressive resistance exercise program, although recruitment rates were low \[[@B46-nutrients-12-01814]\]. Moreover, several studies demonstrated that exercise therapy that consisted of aerobatic exercise, intermittent exercise, and resistance training, improved VO~2~ peak \[[@B48-nutrients-12-01814],[@B49-nutrients-12-01814],[@B50-nutrients-12-01814],[@B51-nutrients-12-01814]\]. Other reports showed that the exercise therapy heightened six minute walk test scoring \[[@B52-nutrients-12-01814],[@B53-nutrients-12-01814]\]. Physical functioning and vitality in QOL parameters also improved in several studies \[[@B52-nutrients-12-01814],[@B54-nutrients-12-01814]\].

Multiple studies showed that the deterioration of renal function in patients with pre-dialysis CKD slowed down after lifestyle changes including exercise and diet modification \[[@B55-nutrients-12-01814]\]. Therefore, exercise therapy combined with appropriate diet therapy is beneficial to suppress CKD progression, particularly in obese and diabetic patients, although the long-term effect on CKD progression from exercise therapy alone remains unknown.

Although amelioration of uremic sarcopenia aims at reducing mortality or hospitalization, very few clinical studies have evaluated death or hospitalization as an outcome for pre-dialysis CKD patients who underwent exercise therapy. In one study that assesses the clinical effect of 6 years of lifestyle intervention in persons with impaired glucose tolerance developing microvascular complications over a 20 year period, renal replacement therapy and mortality did not decrease as a result of interventions that included exercise therapy \[[@B56-nutrients-12-01814]\].

Therefore, exercise therapy may be beneficial for maintaining or improving skeletal muscle performance and exercise endurance in pre-dialysis CKD patients.

3.2. Exercise for Patients Undergoing Hemodialysis {#sec3dot2-nutrients-12-01814}
--------------------------------------------------

In comparison to pre-dialysis CKD and kidney transplant patients, patients on dialysis therapy are more extensively analyzed in terms of the effects of exercise therapy.

For patients on hemodialysis, it is controversial whether exercise could increase skeletal muscle mass \[[@B76-nutrients-12-01814],[@B77-nutrients-12-01814],[@B78-nutrients-12-01814]\]. Exercise-induced enhancement of skeletal muscle strength is shown by several human studies \[[@B47-nutrients-12-01814],[@B57-nutrients-12-01814],[@B58-nutrients-12-01814]\], but not supported by others \[[@B68-nutrients-12-01814],[@B79-nutrients-12-01814],[@B80-nutrients-12-01814]\]. Although clinical evidence of the effect of exercise therapy on mortality in hemodialysis patients is limited, multiple studies support that VO~2~ peak \[[@B59-nutrients-12-01814],[@B60-nutrients-12-01814],[@B61-nutrients-12-01814],[@B62-nutrients-12-01814],[@B63-nutrients-12-01814],[@B64-nutrients-12-01814]\] or VO~2~ max \[[@B65-nutrients-12-01814],[@B66-nutrients-12-01814]\] was increased by exercise intervention, which is better supported by clinical studies with an observation period of six months or longer \[[@B81-nutrients-12-01814]\]. In one report, walking capacity evaluated in a six minute walk test was improved as the result of exercise therapy \[[@B67-nutrients-12-01814]\]. In addition, several studies pointed out that physical activity components of the QOL assessment were enhanced \[[@B68-nutrients-12-01814],[@B69-nutrients-12-01814],[@B70-nutrients-12-01814]\].

Therefore, exercise therapy may help improve exercise endurance, which is supported by a more significant number of clinical studies targeting hemodialysis patients, compared to those targeting pre-dialysis patients. Of note, few clinical studies analyzed uremic sarcopenia in peritoneal dialysis patients \[[@B82-nutrients-12-01814]\].

3.3. Exercise for Kidney Transplant Recipients {#sec3dot3-nutrients-12-01814}
----------------------------------------------

A recent single-blind, randomized controlled trial with adult kidney transplant recipients showed that intensive nutrition intervention including exercise counseling failed to improve physical functioning, such as gait speed, sit to stand, and grip strength, although exercise intervention was limited, i.e., 3 exercise physiologist visits over 12 months \[[@B71-nutrients-12-01814]\]. One report with a small sample size of renal transplant recipients illustrated that VO~2~ peak is increased by exercise \[[@B72-nutrients-12-01814]\]. Several reports showed that physical activity components in QOL are improved by exercise \[[@B72-nutrients-12-01814],[@B73-nutrients-12-01814]\]. However, exercise therapy is not shown beneficial for preserving or improving the graft function in kidney transplant recipients \[[@B74-nutrients-12-01814],[@B75-nutrients-12-01814]\].

4. Experimental Laboratory Tools for Exploration of Uremic Sarcopenia Mechanism {#sec4-nutrients-12-01814}
===============================================================================

A number of nutritional and physical exercise approaches to uremic sarcopenia have been proposed, but these are mostly investigated in the preclinical stage. This underlines the importance of basic research which focuses on uremic sarcopenia. In biological experiments on skeletal muscle, culture myocyte lineage such as mouse C2C12 cells \[[@B83-nutrients-12-01814],[@B84-nutrients-12-01814]\] are widely used in addition to rat L6 cells and skeletal muscle cells (SkMC) established from various animal species such as human, rat, and mouse \[[@B85-nutrients-12-01814]\]. C2C12 cells, subcloned from normal adult C3H mouse leg muscle, are widely used to study in vitro myogenesis and cell differentiation ([Figure 2](#nutrients-12-01814-f002){ref-type="fig"}). Primary cultured cells also are available by growing satellite cells (myoblast) isolated from the animal muscle tissue, although skillful technique is required \[[@B86-nutrients-12-01814]\]. For experimental studies analyzing physiological aspects of skeletal muscle such as the insulin-dependent glucose uptake function, isolation and culture of epitrochlearis muscles in a medium consisting of Krebs Ringer bicarbonate (KRB) buffer, with sodium pyruvate in the presence of insulin, is another established protocol \[[@B87-nutrients-12-01814]\]. To mimic uremic sarcopenia in vitro, chemical compounds known as uremic toxins or uremic serum sampled from CKD animals are added to the culture media.

Obviously, since uremic sarcopenia is a clinical entity and concept in humans, appropriate animal models should be established. A variety of rodent models have been employed so far to recapitulate human uremic sarcopenia. This review will focus on rodent models designed to mimic uremic sarcopenia ([Table 2](#nutrients-12-01814-t002){ref-type="table"}). However, they have limitations in their characterization and in the reproducibility of the condition \[[@B88-nutrients-12-01814]\]. The search for novel models is still warranted. Due to the limited availability and very high costs of using older animals, the use of young animals could be another drawback as a majority of uremic patients with sarcopenia are elderly, complicated by primary, aging sarcopenia.

4.1. Subtotal (5/6) Nephrectomy {#sec4dot1-nutrients-12-01814}
-------------------------------

Subtotal nephrectomy, also known as 5/6 nephrectomy, is probably the most established method to mimic progressive renal failure showcasing renal glomerulosclerosis, interstitial fibrosis, and systemic hypertension, resembling a mass reduction of the kidney in humans. 129/Sv and Swiss-Webster mice can develop more severe damage in terms of renal function and histology compared to C57BL/6 mice. Two different protocols, the ligation model and the ablation model, have been widely adopted. In both models, in order to lighten the burden imposed on an animal, whole procedures are performed in two stages. In approximately two weeks, renal function is deteriorated as shown by the increased urea nitrogen and creatinine in the blood. Sham mice underwent surgery without damaging the kidneys \[[@B89-nutrients-12-01814],[@B111-nutrients-12-01814]\].

The ligation model is more suitable for rats rather than mice as careful surgical technique is required \[[@B112-nutrients-12-01814]\]. After one kidney is removed (contralateral uninephrectomy), typically, 2/3 branches of the renal artery in the rat are ligated, resulting in an obstruction of blood flow to the upper and lower poles of the remaining kidney. Again, this approach cannot be performed in mice due to their limited renal artery branching. The ablation model can be achieved in both rats and mice. At one to two weeks after uninephrectomy, 50--70% of the remaining kidney is removed by polar excision with electrical knife ablation, for instance.

Regarding skeletal muscle manifestation, several groups observed skeletal muscle atrophy presenting with not only bodyweight reduction, but also with a decrease of the total mass and CSA of the muscle compared with sham mice \[[@B89-nutrients-12-01814],[@B90-nutrients-12-01814],[@B91-nutrients-12-01814],[@B92-nutrients-12-01814],[@B93-nutrients-12-01814],[@B94-nutrients-12-01814],[@B95-nutrients-12-01814],[@B96-nutrients-12-01814],[@B97-nutrients-12-01814],[@B98-nutrients-12-01814],[@B99-nutrients-12-01814],[@B100-nutrients-12-01814],[@B101-nutrients-12-01814],[@B102-nutrients-12-01814]\]. Treadmill running distance \[[@B93-nutrients-12-01814],[@B113-nutrients-12-01814]\] and hanging time on the grid with four limbs \[[@B102-nutrients-12-01814]\] were shortened and grip strength had also deteriorated \[[@B89-nutrients-12-01814]\], while some parameters indicating lowered physical activity were not consistently affected \[[@B94-nutrients-12-01814],[@B113-nutrients-12-01814]\]. In addition, mouse ambulation, as indicated by overnight cage activity and swimming velocity, was reduced \[[@B90-nutrients-12-01814]\]. Histologically, skeletal fibrosis was noted \[[@B95-nutrients-12-01814]\] and the number of CD31-positive capillaries was decreased \[[@B102-nutrients-12-01814]\]. In terms of molecular biology, elevation of myostatin, atrogin-1, muscle RING-finger protein-1 (MuRF-1), and an increase in an inflammatory signal such as IL-6, and acceleration of muscle protein degradation are also noted \[[@B91-nutrients-12-01814],[@B94-nutrients-12-01814],[@B96-nutrients-12-01814],[@B99-nutrients-12-01814]\], although alteration of muscular protein synthesis varies between reports.

Extensive research casts light on metabolic aspects targeting the skeletal muscle of this uremic model. For example, the mitochondrial amount measured as the ratio of the mitochondrial DNA to nuclear DNA was decreased in the uremic skeletal muscle \[[@B113-nutrients-12-01814]\]. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator that regulates the genes involved in energy metabolism. In subtotal nephrectomized mice, the PGC-1α expression level was decreased in the skeletal muscle, associated with an increase in the methylation ratio of the cytosine residue at 260 base pairs upstream of the initiation point \[[@B98-nutrients-12-01814],[@B114-nutrients-12-01814]\]. Additionally, 5'-AMP-activated protein kinase (AMPK) has a role as an energy sensor in peripheral tissues and promotes catabolism during energy deficiency. In skeletal muscle, activation of AMPK promotes fatty acid uptake into the mitochondria and subsequent fatty acid oxidation. In subtotal nephrectomized mice, despite a high AMP:ATP ratio, AMPK activation is suppressed not only in the kidney but also in the skeletal muscle \[[@B101-nutrients-12-01814]\]. Autophagy-related molecule expression is also increased in those animal muscles, including Bnip3, Beclin-1, and LC3II mRNAs, indicating that autophagosome--lysosome formation is accelerated in uremic skeletal tissue \[[@B98-nutrients-12-01814],[@B99-nutrients-12-01814]\]. This fused structure forms autolysosomes, in which the sequestered cargos are degraded and recycled for the maintenance of cellular homeostasis \[[@B115-nutrients-12-01814],[@B116-nutrients-12-01814]\]. Thus, it may promote skeletal muscle wasting in CKD \[[@B98-nutrients-12-01814],[@B117-nutrients-12-01814],[@B118-nutrients-12-01814]\].

4.2. Adenine Diet Administration {#sec4dot2-nutrients-12-01814}
--------------------------------

Adenine, also called vitamin B4, is a nucleobase of a purine derivative that is known to be toxic to the kidney. The adenine-induced uremia animal model has gained attention due to its relative ease of implementation without surgery, such as vessel ligation or partial organ ablation. Orally administered adenine is metabolized to 2,8-dihydroxyadenine, which forms crystals in the proximal tubules conferring tubulointerstitial inflammation and fibrosis \[[@B119-nutrients-12-01814]\]. In rodents, a number of studies have modified the concentration and duration of adenine in feed based on what was originally developed \[[@B120-nutrients-12-01814]\]. The male mice are more vulnerable to renal dysfunction than the female mice \[[@B121-nutrients-12-01814]\]. However, regardless of the sex, even with a mixture of adenine with chow, food intake is reduced \[[@B122-nutrients-12-01814]\].

With respect to the uremic effect on skeletal muscle, six to seven week 0.2% (*w*/*w*) adenine-fed mice display skeletal muscle atrophy \[[@B23-nutrients-12-01814],[@B103-nutrients-12-01814]\]. Detailed analysis with liquid chromatography-tandem mass spectrometry revealed the accumulation of uremic toxins and enhanced expression of inflammatory genes in the skeletal muscle \[[@B23-nutrients-12-01814]\]. Interestingly, when an obese "pound" mouse that is deficient in functional leptin receptor isoforms is fed with oral adenine (approximately 4.5 mg/day), kidney damage was worse, representing greater tubular injury with a decrease in kidney mitochondria, a lower tissue ATP level, and enhanced oxidative stress \[[@B104-nutrients-12-01814]\]. Even pound mice with levels of renal function similar to those of adenine-treated wild-type mice also developed muscle atrophy along with lower tissue ATP and phosphate levels. This worsening of the sarcopenic phenotype in adenine-administered pound mice may mimic obesity sarcopenia in the real clinical setting \[[@B24-nutrients-12-01814]\].

4.3. Indoxyl Sulfate Administration {#sec4dot3-nutrients-12-01814}
-----------------------------------

Uremic toxin consists of a group of molecules that are usually filtered and excreted by healthy kidneys but are accumulated in the body when renal clearance is impaired. Those compounds are considered directly harmful to various tissues and organs which have been extensively studied, particularly in the context of uremic cardiovascular disease and kidney damage \[[@B123-nutrients-12-01814]\].

Accumulation of uremic toxins is reported to trigger skeletal muscle loss or dysfunction in CKD \[[@B103-nutrients-12-01814],[@B105-nutrients-12-01814],[@B124-nutrients-12-01814]\]. Therefore, given that indoxyl sulfate (IS) is a major offender in skeletal muscle loss, independent of another uremic milieu, IS administration is sufficient to induce sarcopenia. In an animal with normal renal function, IS is immediately excreted into the urine despite a slightly elevated level of IS concentration. Therefore, to expect IS accumulation in the body, renal clearance would be reduced. At one week after a unilateral kidney was surgically excised, mice were intraperitoneally administrated IS (100 mg/kg/day) for 12 weeks \[[@B105-nutrients-12-01814]\]. This method results in the reduction in weight of the body and tibias anterior (TA), soleus, and gastrocnemius (GC) muscles, despite no significant change in serum creatinine and urea levels. The skeletal manifestation develops simultaneously with an increased expression of myostatin, atrogin-1, IL-6, and TNF-α. Additionally, this type of uremic toxin-mediated skeletal muscle atrophy may target predominantly fast-twitch fibers (Higashihara, Nishi, unpublished). This model is superior in that the IS effect on muscle atrophy can be evaluated.

4.4. Cy/+ Rat, a Han:SPRD Rat with Polycystic Kidney {#sec4dot4-nutrients-12-01814}
----------------------------------------------------

In rodents with uremic sarcopenia, kidney and muscle dysfunction are established within a few weeks or months, while CKD and sarcopenia progress year by year in humans. So, a test subject with slowly progressive renal dysfunction complicated by muscle atrophy would be appropriate for the analysis of uremic sarcopenia. For that reason, Cy/+ rat, a Han:SPRD rat with autosomal dominant polycystic kidney disease (ADPKD) is appropriate, as their kidney function deteriorates month by month. The male Cy/+ rat, a Han:SPRD rat with autosomal dominant polycystic kidney disease, develops persistent azotemia, starting at about 10 weeks of age, which progresses to uremia by about 40 weeks \[[@B125-nutrients-12-01814]\].

Despite no difference in weight, the CSA, and fiber-type proportions of muscle, ADPKD rats demonstrate lower maximum torque in ankle dorsiflexion and shorter time to maximum torque, and longer half relaxation time in dorsiflexion and plantarflexion when the right hind limb is electrically stimulated under general anesthesia \[[@B106-nutrients-12-01814]\]. These rats also express disrupted sarcomeres, engorged muscle mitochondria, and a higher level of proteolytic markers such as atrogin-1 and MuRF-1 in the skeletal muscle and 8OHdG, an oxidative stress marker, in the bloodstream \[[@B107-nutrients-12-01814]\].

4.5. Diabetic Kidney Injury {#sec4dot5-nutrients-12-01814}
---------------------------

Hyperglycemia is a risk factor for muscle mass and functional reduction \[[@B126-nutrients-12-01814]\] and diabetic kidney disease (DKD) is a worldwide public health problem, although the terminology is under discussion. A decreased regenerative capacity after trauma could be a hallmark, in skeletal muscle, of one of the factors contributing to the pathogenesis of sarcopenia \[[@B127-nutrients-12-01814],[@B128-nutrients-12-01814]\]. As an experimental approach in skeletal muscle biology, skeletal muscle regeneration induced by local injection of a toxic chemical such as cardiotoxin is widely used \[[@B129-nutrients-12-01814],[@B130-nutrients-12-01814]\].

In a type 1 diabetes mouse intraperitoneally injected with streptozotocin (STZ, 150 mg/kg) for two consecutive days, skeletal muscles obtained 12 weeks after the second STZ injection were atrophic, representing smaller CSA of muscle fibers and weakened grip together with elevated expression of myostatin, atrogin-1, and MuRf-1 in the muscle \[[@B108-nutrients-12-01814]\]. In addition, in KKAy mice mimicking type 2 diabetes, obese diabetic db/db mice, fat was ectopically accumulated in the lower limb and the deposition was enhanced after local injection of cardiotoxin \[[@B109-nutrients-12-01814]\]. Since type 1 diabetic STZ-treated mice lack this phenotype, insulin resistance may be involved in sarcopenic obesity \[[@B109-nutrients-12-01814]\].

4.6. Kidney Ischemia-Reperfusion Injury {#sec4dot6-nutrients-12-01814}
---------------------------------------

Renal ischemia-reperfusion by temporarily occluding the renal pedicle(s) with nontraumatic clips is an established rodent model that leads to acute kidney injury (AKI) \[[@B131-nutrients-12-01814],[@B132-nutrients-12-01814]\], and thus frequent and major kidney disease with high mortality in clinical settings. To sustain the renal damage, bilateral ischemia-reperfusion injury (IRI) \[[@B133-nutrients-12-01814]\], a unilateral IRI after uninephrectomy \[[@B134-nutrients-12-01814]\], and a unilateral IRI preceding uninephrectomy \[[@B135-nutrients-12-01814]\] are introduced.

Concerning muscle function, bilateral IRI induced by an hour occlusion confers poor motor coordination and balance in the rotarod experiment after one week, while grip strength was not altered \[[@B110-nutrients-12-01814]\]. Deterioration in the rotarod test indicates a deficit in motor coordination or fatigue resistance, so this could be worth investigating, as behavioral deficits occur even with mild renal failure, which may be due to uremic encephalopathy rather than uremic sarcopenia \[[@B136-nutrients-12-01814]\].

5. Exploration of Interventions to Overcome Uremic Sarcopenia {#sec5-nutrients-12-01814}
=============================================================

As a therapeutic approach to uremic sarcopenia, the muscle protective potentials are reviewed with a focus on basic research in vivo. Some of these approaches simultaneously alleviate the kidney injury so that direct influence on skeletal muscles are indistinguishable unless a conditional genetic ablation system is adopted.

5.1. Resistance Training {#sec5dot1-nutrients-12-01814}
------------------------

As a human clinical trial shows, resistance exercise training is capable of preserving lean body mass, nutritional status, and muscle function in patients with moderate chronic kidney disease \[[@B137-nutrients-12-01814]\]. Of note, this effect was confirmed in participants consuming a low-protein diet, but still is a promising approach for uremic sarcopenia in subtotal nephrectomized mice. However, since forcing experimental animals to undergo resistance training is unrealistic, several devices to overcome this hardship have been employed. By removing GC and soleus muscles from both hind limbs to overload plantaris muscles, resistance exercise on the muscle can be simulated. Compared to endurance training (treadmill running), resistance training effectively corrected protein synthesis and levels of mediators of protein synthesis such as phosphorylated mTOR and p70S6K, and showed an increase in muscle progenitor cell number and activity \[[@B91-nutrients-12-01814]\].

Moreover, acupuncture plus low-frequency electrical stimulation is focused on as a treatment to replicate the benefits of resistance exercise through stimulation of muscle contraction. Enforced muscle contraction by this electrical stimulation works to prevent muscle atrophy \[[@B94-nutrients-12-01814]\] and demonstrates autophagy as the promising molecular culprit \[[@B98-nutrients-12-01814]\]. This is interesting in that core autophagy proteins are bound to the endoplasmic reticulum (ER) by the organelle membrane-localized cargo receptors and that ER stress is known to target the kidney \[[@B138-nutrients-12-01814],[@B139-nutrients-12-01814],[@B140-nutrients-12-01814]\] as well as uremic skeletal muscle \[[@B141-nutrients-12-01814]\].

Aquaporin-4 (AQP4) is a water channel expressed at the sarcolemma of fast-twitch skeletal muscle fibers and possibly modulates homeostasis in myofibers through the regulation of water transport and osmotic pressure \[[@B142-nutrients-12-01814],[@B143-nutrients-12-01814]\]. Intriguingly, physical exercise modulates AQP4 expression at the post-translational level in muscles of rodents \[[@B144-nutrients-12-01814]\], whereas AQP4 gene expression is decreased in the aged rodents \[[@B145-nutrients-12-01814]\]. These findings could pinpoint the transporter protein as a key molecule to underlie uremic sarcopenia.

5.2. Mitochondrial Metabolism Activation {#sec5dot2-nutrients-12-01814}
----------------------------------------

There is growing evidence that the skeletal muscle of patients in advanced CKD stages is characterized by mitochondrial dysfunction \[[@B101-nutrients-12-01814],[@B103-nutrients-12-01814],[@B146-nutrients-12-01814]\]. Analysis of human muscle biopsy samples pinpointed lower mitochondrial volume density, lower mitochondrial DNA copy number, and higher BNIP3 content \[[@B146-nutrients-12-01814]\]. Culture experiments of C2C12 myocytes with uremic toxin revealed the upregulation of glycolysis with excess antioxidative response leading to mitochondrial dysfunction and ATP shortage \[[@B103-nutrients-12-01814]\]. Pyruvate dehydrogenase complex converts pyruvate into acetyl-CoA by pyruvate decarboxylation, and acetyl-CoA may then be used in the citric acid cycle to carry out mitochondrial cellular respiration. Miyashita's group elegantly revealed that activation of pyruvate dehydrogenase by dichloroacetate effectively recovered the treadmill running distance of subtotal nephrectomized mice, which was interestingly decreased by dietary protein \[[@B93-nutrients-12-01814]\]. The same lab reported that a diet containing 0.03% (*w*/*w*) 5-aminolevulinic acid (ALA), serving as electron carriers in the mitochondrial electron transport system, increases both skeletal muscle weight and the mitochondrial amount and enhances grip strength and treadmill endurance \[[@B113-nutrients-12-01814]\]. Thus, activation of muscle mitochondria metabolism would serve as a potential strategy for combatting uremic sarcopenia.

5.3. Myostatin Inhibition {#sec5dot3-nutrients-12-01814}
-------------------------

Myostatin is a molecule that suppresses skeletal muscle growth as is dramatically illustrated in myostatin deficient cattle \[[@B147-nutrients-12-01814]\]. Myostatin, also called growth differentiation factor-8 (GDF-8), is a member of the TGF-beta family. The N-terminal peptide is secreted from skeletal muscle and is transformed to a mature form when cleaved by metalloprotease. Myostatin binds to the activin receptor type IIB that has serine/threonine kinase activity, and the signals are transduced through two cascades, Smad2/3 and p38MAPK. Smad2/3 is a transcription factor that not only binds directly to DNA to induce transcription of target genes but also directly binds to Forkhead box O (FoxO) to control the ubiquitin E3 ligases atrogin-1 and MuRF-1, resulting in ubiquitin-proteasome-mediated protein degradation \[[@B148-nutrients-12-01814],[@B149-nutrients-12-01814]\]. In systemic circulation, the function of myostatin is inhibited by binding to follistatin \[[@B150-nutrients-12-01814]\].

In animal models with uremia, myostatin role inhibition has been attempted to attenuate protein catabolism. For instance, anti-myostatin peptibody that was generated as a chimeric peptide-Fc fusion protein was used to treat CKD mice for four weeks resulting in improvement of body weight and less muscle mass loss. At the same time, muscle protein degradation is reduced while, intriguingly, protein synthesis and satellite cell function are enhanced \[[@B92-nutrients-12-01814]\]. The inhibition of myostatin is also helpful in preventing the development of fibrosis in skeletal muscle. Administration of myostatin neutralizing peptibody to CKD rodents reduced the proliferation of fibroblast progenitors and muscle fibrosis \[[@B95-nutrients-12-01814]\].

In humans, the frail elderly showed elevated blood levels of GDF11 that are highly homologous to GDF8, myostatin \[[@B151-nutrients-12-01814]\]. Thus, the myostatin receptor inhibitory signals are hypothesized to exert anabolic effects to enhance skeletal muscle strength in sarcopenia \[[@B152-nutrients-12-01814],[@B153-nutrients-12-01814],[@B154-nutrients-12-01814]\]. Although not applied for uremic sarcopenia, a phase 1 study of anti-myostatin monoclonal antibody LY2495655 in patients with advanced cancer was presented. The treatment improved handgrip strength and physical function scoring. In a clinical study evaluating the effects of the compound in elderly frail people \[[@B152-nutrients-12-01814]\], a lean body mass at 24 weeks was slightly increased, with several measures of improved muscle function. In another trial to assess the safety and efficacy of the agent for 24 weeks after elective total hip arthroplasty \[[@B153-nutrients-12-01814]\], expected alteration of lean body mass and fat mass was not confirmed.

5.4. Activation of Ghrelin Signaling {#sec5dot4-nutrients-12-01814}
------------------------------------

Ghrelin is mainly produced in gastric endocrine cells and has essential effects on energy metabolism regulation, such as increased appetite, weight gain, and gastrointestinal digestive function \[[@B155-nutrients-12-01814]\]. The peptide hormone is modified by fatty acid and promotes muscle mitochondrial oxidation. Intraperitoneal administration of acylated ghrelin (0.1 μmol/kg) three times per week to subtotal nephrectomized mice improved a decline in treadmill exercise endurance, associated with an increase in both the muscle mass and mitochondrial amounts \[[@B114-nutrients-12-01814]\]. The treatment decreased the methylation ratio of the promoter region of PGC-1α in the skeletal muscle, leading to increased mitochondrial content. Additionally, treatment with unacylated ghrelin enhanced mitophagy and normalized oxidative stress in the GC muscle in 5/6 nephrectomized rats. The treatment alsoattenuated inflammation, insulin resistance, and muscle loss \[[@B99-nutrients-12-01814]\].

Anamorelin is developed as a small molecule to enhance protein synthesis by binding the ghrelin/growth hormone secretagogue receptor (GHSR), aiming at the treatment of malignant cachexia \[[@B156-nutrients-12-01814],[@B157-nutrients-12-01814],[@B158-nutrients-12-01814]\]. The drug effect would be divergent in the case that clinical trials for uremic failure is conducted.

5.5. Incretin Modulation {#sec5dot5-nutrients-12-01814}
------------------------

Both glucagon-like peptide-1 (GLP-1) receptor agonist and dipeptidyl peptidase 4 (DPP-4) inhibitors enhance incretin levels, which inhibit glucagon release, which in turn, increases insulin secretion, as a class of oral hypoglycemics used to treat diabetes mellitus type 2. Intraperitoneal administration of exendin-4 (100 ng/day), a GLP-1 receptor agonist, for 12 days \[[@B89-nutrients-12-01814]\] or oral administration of teneligliptin (60 mg/kg), a DPP-4 inhibitor, for 20 weeks \[[@B97-nutrients-12-01814]\], ameliorated body weight loss and muscle atrophy, and improved grip strength using mice with subtotal nephrectomy.

5.6. Carbon Sorbent {#sec5dot6-nutrients-12-01814}
-------------------

In mice with subtotal nephrectomy, the IS level in the circulating blood is elevated, along with a shortening of the running distance to exhaustion determined by treadmill tests, but oral carbon sorbent administration prevented this increase \[[@B159-nutrients-12-01814]\]. After four weeks of oral treatment with 8% (*w*/*w*) AST-120, muscle atrophy was ameliorated in subtotal nephrectomized mice. Since it theoretically binds and partially prevents uremic toxins from being absorbed by the gastrointestinal tract, the sorbent exerts a beneficial effect by reducing systemic accumulation of uremic toxins. Given that the excessive accumulation of uremic toxins confer multiple organ dysfunction in uremia, the sorbent may be useful for treating uremic sarcopenia \[[@B23-nutrients-12-01814],[@B97-nutrients-12-01814]\]. Despite animal studies supporting a renoprotective effect of the drug \[[@B160-nutrients-12-01814],[@B161-nutrients-12-01814]\], human clinical trials, including recent ones, EPPIC-1 and EPPIC-2, have not shown a conclusive beneficial effect \[[@B162-nutrients-12-01814],[@B163-nutrients-12-01814],[@B164-nutrients-12-01814]\] and the drug was less widely adopted by nephrologists compared to other drugs with an established effect on CKD symptoms, such as anemia or electrolyte disorders \[[@B165-nutrients-12-01814]\]. However, suboptimal eradication of the toxin can be a reason for failure when encountering negative results.

5.7. Erythropoiesis Stimulating Agent {#sec5dot7-nutrients-12-01814}
-------------------------------------

Renal anemia is a typical complication of CKD and has been treated with recombinant human erythropoietin (EPO) preparations \[[@B166-nutrients-12-01814]\]. EPO and the receptor have been well documented to transmit signals towards protein kinases, transcription factors, and anti-apoptotic proteins \[[@B167-nutrients-12-01814],[@B168-nutrients-12-01814]\]. Indeed, the presence and bioactivity of the receptor in non-hematopoietic tissues implies that EPO exerts a pleiotropic effect in various tissues and organs \[[@B169-nutrients-12-01814],[@B170-nutrients-12-01814]\]. Intriguingly, endurance time as assessed with a rotarod test in bilateral IRI mice was improved with EPO (1000 U/kg) intraperitoneally injected 30 min prior to surgery \[[@B110-nutrients-12-01814]\]. Additionally, prolyl hydroxylase domain (HIF-PH) inhibitors, which are expected to be erythropoiesis-stimulating agents, are a new class of compounds that focus on enhancing endogenous EPO production \[[@B171-nutrients-12-01814]\]. Interestingly, a decrease in skeletal muscle mass, mitochondrial amount, and exercise capacity in subtotal nephrectomized mice were restored by a 12 week treatment with an orally active HIF-PH inhibitor, MK-8617 (1.5 to 12.5 mg/kg). Increased capillary density in skeletal muscle is ancillary to muscle function improvement, which may be caused by the upregulation of HIF-downstream VEGF expression \[[@B102-nutrients-12-01814]\]. Our laboratory also focused on the pharmacological effect of HIF-PH inhibitor on skeletal myocytes and tissue and also clarified that the pharmacological treatment enhanced glycolysis and suppressed the tricarboxylic acid (TCA) cycle, thus mimicking the Walberg effect in tumors (Takemura, Nishi, unpublished).

5.8. Lipotoxicity Eradication {#sec5dot8-nutrients-12-01814}
-----------------------------

Lipotoxicity is defined as ectopic fat distribution in the peripheral organs with subsequent injurious effects in end organs, including the kidney, \[[@B172-nutrients-12-01814],[@B173-nutrients-12-01814],[@B174-nutrients-12-01814],[@B175-nutrients-12-01814]\] and skeletal muscle \[[@B176-nutrients-12-01814],[@B177-nutrients-12-01814],[@B178-nutrients-12-01814]\]. In terms of cellular energy production, long-chain fatty acyl-CoA is esterified with carnitine in the cytoplasm, and then, the carnitine shuttle serves to carry it from the cytosol to the mitochondria, and thus, the carnitine nutritional supplement is expected to enhance or normalize long-chain fatty acid metabolism. The administration of L-carnitine (560 mg/kg) for 24 weeks significantly suppressed this impaired exercise capacity. Subtotal nephrectomy in mice induces lowered expression of PGC-1α, autophagy induction, and even muscle fiber switch from type I to type II in the GC muscle, all of which were restored with L-carnitine treatment \[[@B97-nutrients-12-01814]\].

5.9. Small RNA and Lnc RNA {#sec5dot9-nutrients-12-01814}
--------------------------

Given that RNA has been approved as the newest therapeutic modality in humans \[[@B179-nutrients-12-01814]\], these approaches can provide options for treating uremic sarcopenia in the future. By utilizing STZ-induced kidney injury and uremic sarcopenia in mice, the intramuscular injection of adeno-associated virus (AAV)-miR-23a/27a to TA reduced the abundance of atrgoin-1 and MuRF-1 in skeletal muscles. In addition, this viral vector injection attenuated the diabetes-induced reduction in muscle CSA and muscle function along with attenuation of renal function and fibrosis \[[@B108-nutrients-12-01814]\]. Long noncoding RNAs (lncRNAs) are defined as \>200 nucleotide RNAs lacking the protein-coding potential. Besides, lncRNA arrays identified Atrolnc-1 as one gene that is robustly elevated in atrophying muscles from mice with cachexia. They found that depressed insulin signaling stimulates the transcription factor C/EBP-α in binding to the promoter of Atrolnc-1 and promotes the expression of Atrolnc-1. It interacts with the A20 binding inhibitor of NF-κB-1 (ABIN-1), resulting in enhanced NF-κB activity plus MuRF-1 transcription, leading to muscle atrophy. Surprisingly, AAV mediated silencing of Atrolnc-1 in TA muscle in mice with subtotal nephrectomy and restored the ratio of muscle weight to tibia bone length and CSA of the myofibers \[[@B100-nutrients-12-01814]\].

6. Conclusions {#sec6-nutrients-12-01814}
==============

Clinicians should be aware that sarcopenia occurs not only in the elderly but also secondarily, due to chronic illnesses such as cancer, heart failure, and CKD, and negatively affects daily physical activity. When found in coexistence with CKD, the presence of sarcopenia can be a life prognostic factor. The measures that can be taken to improve this condition are dietary therapy and safe exercise. However, it has yet to be determined how much and what kinds of exercise will benefit individual patients at various stages of disease and fitness. There is an urgent need for an appropriate experimental model that can verify the pathology and determine treatment of uremic sarcopenia. Further research in the field will yield a new clinical and biological evidence to comprehensively understand the mechanisms and mediators of interaction between the skeletal muscle and the kidney, which may alter recommendations for diet and exercise strategies against CKD.
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![Suggested exercise therapy intervention for patients with uremic sarcopenia. (**A**) Biceps curl as an example of resistance training. A person holds one bottle with each hand down, raises it until it reaches his or her shoulders' height and slowly lowers them back down after a short pause. A plastic bottle filled with water as a dumbbell can be used. (**B**) Walking in place as an example of aerobic exercise. A person lifts his or her knee up until the calf and thigh form a right angle, then, lowers that leg and repeats with the other leg. The above steps are repeated 10 times. This movement combines traditional running movements with knee lifting.](nutrients-12-01814-g001){#nutrients-12-01814-f001}

![General protocol for mouse skeletal C2C12 myoblast differentiation to myotubes. The immortal line of mouse skeletal myoblasts is kept in culture, avoiding high confluence culture conditions. Replacement of C2C12 myoblast culture medium with growth/differentiation medium containing the lower concentration of horse serum for five to seven days promoted differentiation to C2C12 myotube, which are fused with each other and represent a polynuclear syncytial morphology, as shown with Giemsa staining (left and middle panels) and immunofluorescence staining with antibody against myosin heavy chain and Höchst 33,258 (right panel). FBS: fetal bovine serum.](nutrients-12-01814-g002){#nutrients-12-01814-f002}

nutrients-12-01814-t001_Table 1

###### 

Exercise therapy approach to patients with various stages of CKD.

                                 Skeletal Muscle Strength                                                                                         VO~2~ Peak/VO~2~ Max                                                                                                                                                                                                     6-Min Walk                                                      Physical Activity (QOL)                                                                GFR Reduction                                               Hospitalization                      Mortality
  ------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------ ------------------------------------
  Pre-dialysis CKD               \+ \[[@B44-nutrients-12-01814],[@B45-nutrients-12-01814],[@B46-nutrients-12-01814],[@B47-nutrients-12-01814]\]   \+ \* \[[@B48-nutrients-12-01814],[@B49-nutrients-12-01814],[@B50-nutrients-12-01814],[@B51-nutrients-12-01814]\]                                                                                                        \+ \* \[[@B52-nutrients-12-01814],[@B53-nutrients-12-01814]\]   \+ \* \[[@B52-nutrients-12-01814],[@B54-nutrients-12-01814]\]                          \+ \* \[[@B55-nutrients-12-01814]\]                         → \* \[[@B56-nutrients-12-01814]\]   → \* \[[@B56-nutrients-12-01814]\]
  Hemodialysis                   \+ \[[@B47-nutrients-12-01814],[@B57-nutrients-12-01814],[@B58-nutrients-12-01814]\]                             \+ \[[@B59-nutrients-12-01814],[@B60-nutrients-12-01814],[@B61-nutrients-12-01814],[@B62-nutrients-12-01814],[@B63-nutrients-12-01814],[@B64-nutrients-12-01814],[@B65-nutrients-12-01814],[@B66-nutrients-12-01814]\]   \+ \[[@B67-nutrients-12-01814]\]                                \+ \[[@B68-nutrients-12-01814],[@B69-nutrients-12-01814],[@B70-nutrients-12-01814]\]   NA                                                          Unknown                              Unknown
  Kidney transplant recipients   → \[[@B71-nutrients-12-01814]\]                                                                                  \+ \[[@B72-nutrients-12-01814]\]                                                                                                                                                                                         Unknown                                                         \+ \[[@B72-nutrients-12-01814],[@B73-nutrients-12-01814]\]                             → \[[@B74-nutrients-12-01814],[@B75-nutrients-12-01814]\]   Unknown                              Unknown

\* analyzed in mainly pre-dialysis obese CKD patients with DKD. CKD: chronic kidney disease, QOL: quality of life, DKD: diabetic kidney disease: NA: not applicable

nutrients-12-01814-t002_Table 2

###### 

Experimental animal models: implication in uremic sarcopenia.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                  Skeletal Muscle Manifestation                                                Literature
  ----------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subtotal (5/6) nephrectomy                      Muscle atrophy\                                                              \[[@B89-nutrients-12-01814],[@B90-nutrients-12-01814],[@B91-nutrients-12-01814],[@B92-nutrients-12-01814],[@B93-nutrients-12-01814],[@B94-nutrients-12-01814],[@B95-nutrients-12-01814],[@B96-nutrients-12-01814],[@B97-nutrients-12-01814],[@B98-nutrients-12-01814],[@B99-nutrients-12-01814],[@B100-nutrients-12-01814],[@B101-nutrients-12-01814],[@B102-nutrients-12-01814]\]
                                                  ↓Treadmill running endurance\                                                
                                                  ↓Grip strength, hanging time on the grid\                                    
                                                  ↓Overnight ambulation\                                                       
                                                  ↓Swimming velocity\                                                          
                                                  ↑Expression of myostatin, atrogin-1, MuRF-1, IL-6, Binp3, Beclin-1, LC3II\   
                                                  ↓Expression of PGC1α, andAMPK                                                

  Adenine diet administration                     Muscle atrophy\                                                              \[[@B103-nutrients-12-01814],[@B104-nutrients-12-01814]\]
                                                  ↓Concentration of ATP and intracellular phosphate                            

  Indoxyl sulfate administration                  Muscle atrophy\                                                              \[[@B105-nutrients-12-01814]\]
                                                  ↑Expression of myostatin, atrogin-1, IL-6, TNF-α                             

  Cy/+ rat\                                       ↓Maximum torque in ankle dorsiflexion\                                       \[[@B106-nutrients-12-01814],[@B107-nutrients-12-01814]\]
  (Han:sPRD rat with polycystic kidney disease)   ↑Relaxation time in hind limb dorsiflexion and plantarflexion\               
                                                  ↑Expression of atrogin-1, MuRF-1, oxidative stress markers                   

  Diabetic kidney disease                         Muscle atrophy\                                                              \[[@B108-nutrients-12-01814],[@B109-nutrients-12-01814]\]
                                                  ↓Muscle regeneration\                                                        
                                                  ↑Expression of myostatin, atrogin-1, MuRF-1                                  

  Kidney ischemia-reperfusion injury              ↓Motor coordination and balance                                              \[[@B110-nutrients-12-01814]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑: increased or enhanced, ↓: decreased or deteriorated.
